About viriom
Viriom Inc. is a late-clinical stage company developing novel therapy and prevention treatments against HIV and hepatitis B virus (HBV). Viriom's pipeline includes: Elpida® (elsulfavirine), a best in its class NNRTi, now expecting the first market authorization; fixed doze combinations with nucleoside reverse transcriptase inhibitors; extended release weekly oral formulation; VM1500A - a long acting injectable therapy and pre-exposure prophylaxis. Viriom is also developing a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®) to treat HIV and hepatitis B patients.
“HOPE HEALTH HAPPINESS FOR ALL.
LET NONE LIVE DEPRIVED.
”
Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.
Here, we compare the risk/benefit profiles of three leading oral antiviral drugs: Favipiravir, Molnupiravir, and Paxlovid. These compounds have distinct features supporting their targeted use by persons with COVID-19 disease.
Avifavir, the first direct oral antiviral drug was registered in Indonesia under an accelerated procedure based on data of the GCP phase II-III clinical trial conducted in 30 clinical centers in April-September 2020 involving 460 patients.
Viriom, Inc. (Viriom) announced today the initiation of a Phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients. The earlier findings of a Phase 1 study investigating safety and pharmacokinetics with single and multiple dosing of this formulation were presented at CROI 2020 in Boston.
SAN DIEGO, Dec. 3, 2019 -- Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Viriom Inc. (San Diego, CA), has won a grant award in the city of Shaoxing, Zhejiang province, to establish its affiliate in Mainland China. Viriom opened a representative office in Beijing in 2017 and is establishing an affiliate in Hong Kong as part of its five-year plan of drug development and technology transfer to attend to markets, including Greater China, Thailand and Indonesia, where over 5 million people live with an HIV infection.
Viriom Inc (San Diego, CA) signed a licensing agreement with P.T. Lloyd Pharma Indonesia as a part of its global strategy to help combat HIV drug resistance problem in developing markets by using innovative, safe and efficacious treatment and prevention options with Elpida® as well as other drugs from Viriom HIV and HBV portfolio.
SAN DIEGO, June 3, 2019 -- Iain Dukes, CEO of Viriom Inc (San Diego, CA), presented Viriom's strategy on high growth developing markets, which includes obtaining a market authorization in China, at the 11th ChinaBio Annual International Partnering Conference in Shanghai.
Viriom Inc. is pleased to announce the appointment of Iain Dukes, M.A., D.Phil., as its new CEO. Dr. Dukes brings to Viriom over 20 years of extensive experience in drug discovery, pharmaceutical research and business development, as well as in leadership and consulting for numerous biotech and venture capital organizations.
Viriom China has been named the only foreign finalist of the 2018 Zhongguancun International Frontier Science and Technology Innovation Competition. The Zhongguancun government offered Viriom China advantageous terms for research and manufacturing activities. It also supports Viriom’s regulatory and financing activities in China.